Polpharma is the largest Polish manufacturer of pharmaceuticals and among the top 20 generic drug manufacturers in the world with sales of USD 1 billion per year. It employs more than 7,000 people and has 7 manufacturing plants and 6 research and development centres worldwide. Polpharma Group’s portfolio includes about 600 products, and another 200 are being developed.
Polpharma manufactures a wide range of prescription drugs and pharmaceuticals for in-patient care, which has a leading share in the key therapeutic areas in Poland. Polpharma specializes in pharmaceutical preparations used in cardiology, gastroenterology and neurology. Over the counter medications (OTC) account for a significant part of its product portfolio. They develop their operations in the field of biotechnological drugs: biosimilars and biobetters. They are also one of the largest Polish manufacturers of active pharmaceutical ingredients (APIs) which compete successfully in the developed markets of the EU and the US.
Polpharma provides drugs of the highest quality and reliable medical knowledge. It is one of the most innovative companies in Poland according to the ranking prepared by the Institute of Economic Sciences of the Polish Academy of Sciences.